TMU Research Center of Cancer Translational Medicine

Emily Pei-Ying Lin, M.D. Ph.D.

  • Associate Professor of Medicine
  • Taipei Medical University, Taiwan
  • Attending Physician,Department of Medicine Taipei Medical University Hospital, Taiwan
  • Director,Center for Precision Health and Quantitative Sciences Taipei Medical University Hospital, Taiwan
  • Adjoint Associate Professor, Department of Biostatistics Vanderbilt University Medical Center, TN, USA

Contact Information
E-mail: emilypylin@tmu.edu.tw; pei.y.lin@vumc.org

Education
1996-2003 M.D. College of Medicine, Taipei Medical University
2008-2015 Ph.D. Taiwan International Graduate Program in Molecular Medicine, National Yang-Ming University and Academia Sinica

Experience

  • 2023~ Associate Professor, School and College of Medicine, Taipei Medical University,Taipei, Taiwan
  • 2023~ Adjoint Associate Professor, Department of Biostatistics, Vanderbilt University,Medical Center, Nashville, Tennessee, USA
  • 2023~ Associate Professor (Joint Appointment), Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan
  • 2023~ Associate Professor (Joint Appointment), Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
  • 2021~ Director, Center for Precision Health and Quantitative Sciences, Taipei Medical University Hospital, Taipei, Taiwan
  • 2020~ Attending Physician, Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan
  • 2022 Coordinator, Precision Oncology Team, Taipei Medical University
  • 2021-2023 Associate Director, Department of Medical Research, Taipei Medical University Hospital, Taipei, Taiwan
  • 2021-2023 Assistant Professor, School and College of Medicine, Taipei Medical University,Taipei, Taiwan
  • 2021-2022 Director, Center for Precision Medicine and Translational Cancer Research, Taipei Medical University Hospital, Taipei, Taiwan
  • 2020-2023 Adjoint Assistant Professor, Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
  • 2020 Attending Physician of Chest Medicine and Director of Medical Research, Fu Jen Catholic University Hospital, New Taipei City, Taiwan
  • 2020 Assistant Professor, Fu Jen Catholic University College of Medicine, New Taipei City, Taiwan
  • 2018-2020 Visiting Scholar, Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
  • 2015-2019 Attending Physician, Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan
  • 2015-2018 Adjunct Attending Physician, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
  • 2008-2019 Adjunct Attending Physician, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • 2006-2008 Clinical Fellow, Division of Chest Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • 2003-2006 Resident, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • 2002-2003 Rotating Intern, National Taiwan University Hospital, Taipei, Taiwan

Honors

  • 2024: TOS Young Investigator Award for Cancer Research, Taiwan.
  • 2024: VICTR award. Vanderbilt University Medical Center, Nashville, TN, USA.
  • 2022: Outstanding Research Award, Taipei Medical University, Taipei, Taiwan.
  • 2020: VICTR award. Vanderbilt University Medical Center, Nashville, TN, USA.
  • 2019: Fellowship award, Method in Clinical Cancer Research. Zeist, Netherland.
  • 2019: Fellowship award, IASLC Targeted Therapies of Lung Cancer Meeting. Santa Monica,CA, USA.
  • 2016: Young investigator communication workshop award. WCLC. Vienna, Austria.
  • 2011: Outstanding presentation award. Joint Molecular Medicine Program Retreat. Institute of Biomedical Sciences, Academia Sinica, Taiwan.
  • 2009: Fellowship award, Molecular Biology in Clinical Oncology. Aspen, CO, USA.
  • 2009: AACR-ITO EN, Ltd. Scholar-in-Training Award. The 100th AACR Annual Meeting. Denver, CO, USA.
  • 2003: Dr. Tu Tsung-Ming award

Specialties and Research Interests

  1. Internal Medicine
  2. Pulmonary and Critical Care Medicine
  3. Thoracic Oncology
  4. Cancer Biology and Molecular Cancer Biology
  5. Translational Cancer Research
  6. Precision Medicine and Precision Oncology

Journal Reviewer

  • JAMA Oncology
  • Journal of Thoracic Oncology
  • Experimental Hematology & Oncology
  • Journal of Biomedical Science
  • BMC Cancer
  • JTO Clinical and Research Reports
  • The International Journal of Biological Markers
  • Frontiers in Genetics

Selected Publications within Five Years (2020~2024)

(A). Journal
  1. Huang BT, Lai WY, Yeh CL, Tseng YT, Peck K, Yang PC, Lin EP*. AptBCis1, an aptamercisplatin
    conjugate, is effective in lung cancer leptomeningeal carcinomatosis. ACS Nano.
    2024;18(41):27905-27916. (IF=15.8)
  2. Lin EP, Hsu CY, Berry L, Bunn P, Shyr Y*. Analysis of Cancer Survival Associated With
    Immune Checkpoint Inhibitors After Statistical Adjustment: A Systematic Review and Metaanalyses.
    JAMA Netw Open. 2022;5(8):e2227211. (IF=13.8)
  3. Lin EP, Hsu CY, Chiou JF, Horn L, Bunn P, Yang JC, Yang PC, Adjei A, Shyr Y*. Cox
    Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors
    (ICI): Cox-TEL Adjustment and Meta-analyses of PD-L1 Expression and ICI Survival Benefit.
    J Thorac Oncol. 2022;17(12):1365-1374. (IF=21.1)
  4. Lin EP*, Huang LC, Whisenant J, York S, Osterman T, Lewis J, Iams W, Skotte E, Cass A,
    Hsu CY, Shyr Y, Horn L. Associations between Influenza Vaccination and Severity of Immune-
    Related Adverse Events in Patients with Advanced Thoracic Cancers on Immune Checkpoint
    Inhibitors. ERJ Open Research. 2022;8(4):00684-2021. (IF=4.3)
  5. Lin EP, Huang BT, Lai WY, Tseng YT, Yang SC, Kuo HC, Yang PC*. PINK1-mediated
    inhibition of EGFR dimerization and activation impedes EGFR-driven lung tumorigenesis.
    Cancer Res. 2021;81(7):1745-1757. (IF=12.5)
  6. Hsu CY, Lin EP, Shyr Y*. Development and Evaluation of a Method to Correct Misinterpretation of Clinical Trial Results with Long-term Survival. JAMA Oncol.2021;7(7):1041-1044. (IF=28.4)
  7. Wang M, Lin EP, Huang LC, Li CY, Shyr Y, Lai CH*. Mortality of cardiovascular events in COPD patients with preceding hospitalized acute exacerbation. Chest. 2020;158(3):973-985.
    (Co-first) (IF=9.3)
  8. Das S, Ciombor KK, Haraldsdottir S, Pumpalova Y, Sahin IH, Pineda G, Shyr Y, Lin EP, Hsu CY, Chu SK, Goff LW, Cardin DB, Bilen MA, Fisher GA, Wu C, Berlin J*. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.Oncologist. 2020;25(8):669-679. (IF=5.8)
(B). Conference Paper
  1. Lin EP*, Huang BT, Yang PC. AptBCis1: A novel DNA therapeutics for lung cancer leptomeningeal carcinomatosis. WCLC San Diego, USA. 2024.
  2. Huang BT, Lai WY, Yeh CL, Tseng YT, Yang PC, Lin EP*. APC-1, a novel aptamer-cisplatin
    conjugate, exhibits promising anti-tumor effect in lung cancer. WCLC Singapore. 2023.
  3. Lin EP, Hsu CY, Chiou JF, Horn L, Bunn P, Yang JC, Yang PC, Adjei A, Shyr Y*.Overestimation with Cox HR: Cox-TEL-Adjusted Associations of PD-L1 Expression with
    Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer. WCLC Austria. 2022.